Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMDGlobeNewsWire • 07/06/22
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDGlobeNewsWire • 06/24/22
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMDGlobeNewsWire • 06/09/22
Adverum Biotechnologies Announces New Data at the Macula Society's 2022 Annual MeetingGlobeNewsWire • 06/02/22
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene TherapyGlobeNewsWire • 05/19/22
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022GlobeNewsWire • 05/17/22
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual MeetingGlobeNewsWire • 05/01/22
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDAGlobeNewsWire • 04/06/22
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/29/22
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare ConferenceGlobeNewsWire • 02/28/22
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical OfficerGlobeNewsWire • 02/07/22
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development OfficerGlobeNewsWire • 01/06/22
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone MonochromacyGlobeNewsWire • 01/04/22
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022GlobeNewsWire • 12/21/21
Adverum Biotechnologies Appoints Rupert D'Souza, Ph.D., M.B.A. as Chief Financial OfficerGlobeNewsWire • 12/06/21
Moore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law FirmNewsfile Corp • 11/30/21